Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (11-20 of 124) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2017
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech RepublicEva Havrdova, Gisela Kobelt, Jenny Berg, et al.
Annals of the New York Academy of Sciences|October 4, 2007
Natalizumab in the treatment of patients with multiple sclerosis: first experienceHelena Mareckova, Eva Havrdova, Eva Krasulova, et al.
Journal of Neuroengineering and Rehabilitation|April 19, 2015
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5)Jana Lizrova Preiningerova, Klara Novotna, Jan Rusz, et al.
Plos One|November 21, 2012
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort studyTomas Kalincik, Manuela Vaneckova, Michaela Tyblova, et al.
Neuro Endocrinology Letters|September 4, 2008
Secondary-progressive form of multiple sclerosis: MRI changes versus clinical statusMartin Masek, Manuela Vaneckova, Jan Krasensky, et al.
Neuro Endocrinology Letters|January 27, 2016
The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalusLucie Sosvorova, Radmila Kanceva, Josef Vcelak, et al.
Journal of Neurology|December 31, 2013
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosisGavin Giovannoni, Ernst-Wilhelm Radue, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2013
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT studyEva Havrdova, Gavin Giovannoni, Dusan Stefoski, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
European Neurology|March 20, 2009
Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosisManuela Vaneckova, Zdenek Seidl, Jan Krasensky, et al.
Pageof 13

Showing results (11-20 of 124) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2017
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech RepublicEva Havrdova, Gisela Kobelt, Jenny Berg, et al.
Annals of the New York Academy of Sciences|October 4, 2007
Natalizumab in the treatment of patients with multiple sclerosis: first experienceHelena Mareckova, Eva Havrdova, Eva Krasulova, et al.
Journal of Neuroengineering and Rehabilitation|April 19, 2015
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5)Jana Lizrova Preiningerova, Klara Novotna, Jan Rusz, et al.
Plos One|November 21, 2012
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort studyTomas Kalincik, Manuela Vaneckova, Michaela Tyblova, et al.
Neuro Endocrinology Letters|September 4, 2008
Secondary-progressive form of multiple sclerosis: MRI changes versus clinical statusMartin Masek, Manuela Vaneckova, Jan Krasensky, et al.
Neuro Endocrinology Letters|January 27, 2016
The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalusLucie Sosvorova, Radmila Kanceva, Josef Vcelak, et al.
Journal of Neurology|December 31, 2013
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosisGavin Giovannoni, Ernst-Wilhelm Radue, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2013
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT studyEva Havrdova, Gavin Giovannoni, Dusan Stefoski, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
European Neurology|March 20, 2009
Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosisManuela Vaneckova, Zdenek Seidl, Jan Krasensky, et al.
Pageof 13